A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

Part of paid clinical trials in Denver, Colorado.

Sponsor
Normunity AccelCo, Inc.
Study ID
NCT07182149
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • NRM-823 — DRUG
    NRM-823 is a bispecific T-Cell Engager

Study Details

This study is being done to find out of NRM-823 is safe and can treat participants with locally advanced or metastatic solid tumors.

Key Dates

Start date
Oct 30, 2025
Status verified
Feb 2026
Primary completion
May 30, 2027
Completion
Oct 31, 2028

Study Design

Enrollment
150 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: NRM-823
    Administered per protocol requirements

Primary Outcome Measure

Incidence of treatment-emergent adverse events (TEAE) [ Time Frame: From enrollment until 30 days post the last dose received by a participant ]

Central Contacts

Locations (9)

FacilityCityStateZIPSite coordinators
Normunity Investigational SiteDenverColorado80220-
Normunity Investigational SiteNew HavenConnecticut06519-
Normunity Investigational SiteMinneapolisMinnesota55425-
Normunity Investigational SiteMaumeeOhio43537-
Normunity Investigational SitePhiladelphiaPennsylvania19107-
Normunity Investigational SiteNashvilleTennessee37203-
Normunity Investigational SiteDallasTexas75230-
Normunity Investigational SiteSan AntonioTexas78229-
Normunity Investigational SiteFairfaxVirginia22031-

Find similar trials in Denver, CO

By condition
Cervical cancerEndometrial cancerHead and neck cancerLung cancerOvarian cancer
By specialty
OncologyGynecologic oncologyWomen's healthENTLung oncologyLung disease
By research site
Normunity Investigational Site· Denver, CONormunity Investigational Site· New Haven, CTNormunity Investigational Site· Minneapolis, MNNormunity Investigational Site· Maumee, OHNormunity Investigational Site· Philadelphia, PANormunity Investigational Site· Nashville, TN

Related Studies